https://www.selleckchem.com/products/p22077.html
To examine the ability of the Decipher test to predict early biochemical recurrence after radical prostatectomy and to impact clinical decisions in advance of metastasis and death. We identified Decipher tests ordered after radical prostatectomy for adverse pathology in men treated for prostate cancer between 1/1/14 and 8/31/18. Biochemical recurrence was defined as prostate-specific antigen 0.02ng/mL. Decipher score is reported as lower risk ( 0.6) and higher risk ≥ 0.6. Kaplan-Meier analysis was used to examine the relations
Like
Comment
Share
